(Q42164949)

English

Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

scientific article published on February 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

0 references

congestive heart failure

1 reference

based on heuristic

inferred from title

author name string

Mariantonietta Cicoira

1

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Luisa Zanolla

2

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Lorenzo Franceschini

3

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Andrea Rossi

4

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Giorgio Golia

5

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Prisca Zeni

6

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Beatrice Caruso

7

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Piero Zardini

8

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

language of work or name

0 references

publication date

1 February 2002

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

403-407

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Left atrial filling volume can be used to reliably estimate the regurgitant volume in mitral regurgitation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Captopril in heart failure. A double blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium Retention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Relation of cardiovascular disease to potassium and magnesium deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Aldosterone reduces baroreceptor discharge in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902261-5

7 January 2021

Identifiers

10.1016/S0002-9149(01)02261-5

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42164949&oldid=1935065987"